Date:10/24/2010

e deliver mid to long term growth to our shareholders. We have proven research and development capabilities and a robust vaccine development pipeline with promising market potential. With stringent quality assurance programs in place at our manufacturing facilities, we are poised to benefit from new China GMP standards that are anticipated to be issued in the coming year. We are on track with our capacity expansion initiatives in advance of the commercialization of our pipeline products. Moreover, we are actively seeking international collaborations and potential expansion opportunities."

The preliminary sales range is a preliminary unaudited estimate for the quarter ended September 30, 2010. The Company's financial results for third quarter of 2010 have not been finalized, and remain subject to the completion of its normal quarter-end closing procedures and possible change.

Conference Call DetailsThe Company will host a conference call on Monday, October 25, 2010 at 8:00 a.m. EDT (October 25, 2010 at 8:00 pm China Standard Time) to review the Company's selected preliminary unaudited sales range for the third quarter ended September 30, 2010 and revised full year 2010 sales expectations. To access the conference call, please dial 1-877-407-4018 (USA) or 1-201-689-8471 (international). A replay of the call will be available from 11:00 a.m. EDT on October 25, 2010 to November 8, 2010 at midnight. To access the replay, please dial 1-877-870-5176 (USA) or 1-858-384-5517 (international) and the replay pin number 359546.

A live audio webcast of the call will also be available from the Investors section on the corporate web site at http://www.sinovac.com. A webcast replay can be accessed on the corporate website beginning October 25, 2010 and the replay will remain available for 30 days.

About SinovacSinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, developme
'/>"/>

SOURCE Sinovac Biotech Ltd. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine technology :

1. Sinovac Selected by Beijing CDC to Supply Seasonal Flu Vaccine Anflu(R) to Beijing Citizens
2. Sinovac Receives Drug Registration Certificate from Hong Kong Department of Health for Seasonal Flu Vaccine Anflu(R)
3. Sinovac to Host Conference Call to Report Second Quarter 2010 Financial Results
4. Sinovac Holds 2010 Annual Meeting of Shareholders
5. Sinovac Schedules 2010 Annual Meeting of Shareholders
6. Sinovac Selected by Beijing CDC to Supply Hepatitis A Vaccine Healive(R)
7. Sinovac Announces Plan to Launch Offering of Common Shares
8. Sinovac Announces Recent Developments
9. Sinovac Obtains Fifth H1N1 Vaccine Order from Chinese Central Government
10. Sinovac Named One of Chinas Top 10 Most Competitive Companies Listed Overseas in 2009
11. Sinovacs CEO Weidong Yin Nominated for China Central Televisions Prestigious Economic Man-of-the-Year Award